Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Clinical trial NCT02648711 · TERMINATED
Trial details
- NCT number
- NCT02648711
- Sponsor
- NewLink Genetics Corporation
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-01
- Primary completion
- 2017-10-17
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.